- Home
- HYFM vs COCP Comparison
HYFM vs COCP Comparison
Compare HYFM & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYFM
- COCP
- Stock Information
- Founded
- HYFM 1977
- COCP 2006
- Country
- HYFM United States
- COCP United States
- Employees
- HYFM N/A
- COCP N/A
- Industry
- HYFM Industrial Machinery/Components
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- HYFM Industrials
- COCP Health Care
- Exchange
- HYFM Nasdaq
- COCP Nasdaq
- Market Cap
- HYFM 15.0M
- COCP 15.4M
- IPO Year
- HYFM 2020
- COCP N/A
- Fundamental
- Price
- HYFM $2.91
- COCP $1.08
- Analyst Decision
- HYFM
- COCP Strong Buy
- Analyst Count
- HYFM 0
- COCP 1
- Target Price
- HYFM N/A
- COCP $6.00
- AVG Volume (30 Days)
- HYFM 35.7K
- COCP 270.3K
- Earning Date
- HYFM 11-06-2025
- COCP 11-12-2025
- Dividend Yield
- HYFM N/A
- COCP N/A
- EPS Growth
- HYFM N/A
- COCP N/A
- EPS
- HYFM N/A
- COCP N/A
- Revenue
- HYFM $161,102,000.00
- COCP N/A
- Revenue This Year
- HYFM N/A
- COCP N/A
- Revenue Next Year
- HYFM $37.86
- COCP N/A
- P/E Ratio
- HYFM N/A
- COCP N/A
- Revenue Growth
- HYFM N/A
- COCP N/A
- 52 Week Low
- HYFM $1.50
- COCP $1.02
- 52 Week High
- HYFM $8.55
- COCP $3.26
- Technical
- Relative Strength Index (RSI)
- HYFM 40.79
- COCP 33.90
- Support Level
- HYFM $2.62
- COCP $1.03
- Resistance Level
- HYFM $3.42
- COCP $1.09
- Average True Range (ATR)
- HYFM 0.24
- COCP 0.06
- MACD
- HYFM 0.00
- COCP -0.00
- Stochastic Oscillator
- HYFM 33.72
- COCP 22.22
About HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).